

The Newsletter of the Department of Pathology and Laboratory Medicine  
at NewYork-Presbyterian Hospital/Weill Cornell Medical Center

## Contents

1

Research Highlights

2

Focus

3-6

Keynotes

6

Newly Awarded Grants  
In Pathology

7-9

Faculty Publications

10

Resident's Corner

12

Post-Graduate Courses

## Research Highlights

by Daniel M. Knowles, MD

### Ubiquitin-Proteolytic Control of DNA Repair and Hematopoiesis




Pengbo Zhou, PhD

**Dr. Pengbo Zhou**, now an Associate Professor of Pathology and Laboratory Medicine with tenure, received his PhD in Biological Chemistry from the University of Michigan and did his postdoctoral training with Dr. Elaine Fuchs at the University of Chicago Pritzker School of Medicine and Dr. Peter Howley at Harvard Medical School. He joined the Weill Cornell

Medical College in 1999 as an assistant professor. Dr. Zhou is a Scholar of the Leukemia and Lymphoma Society and a recipient of the Irma T. Hirsch Career Scientist award. His research program is supported by the National Institutes of Health, the STARR Cancer Consortium, the Tri-Institutional Stem Cell Initiative from the STARR Foundation, the NYSTEM program of the New York State Department of Health, the Irma T. Hirsch Trust, and the Leukemia and Lymphoma Society.

#### Ubiquitin-Proteolytic Control of DNA Repair and Hematopoiesis

Selective degradation of specific cellular proteins by the ubiquitin-proteasome pathway is essential for a variety of vital functions, including cell cycle, signal transduction, transcriptional regulation, apoptosis, and DNA repair. Dr. Zhou's laboratory is using a combination of biochemical, genetic and cell biological approaches to study how ubiquitin-dependent proteolysis regulates some of these fundamental biological processes, and how these precisely controlled proteolysis processes go awry leading to cancer development. His current research focuses on three areas:



**Figure 1:** Detection of micropore UV irradiation-induced DNA lesions by the DDB DNA damage sensors. The arrowheads mark DDBs on DNA damage sites.

#### (1) CUL4A in DNA Repair and Carcinogenesis

The Cullin family of proteins function as molecular scaffolds that organize the assembly of the multisubunit ubiquitin ligase complexes. Dr. Zhou is currently focusing on studying the Cullin4A (CUL4A) ubiquitination machinery. The *CUL4A* gene is amplified or over-expressed in breast cancer, liver cancer and a variety of other tumor types. However, the proteolytic targets, as well as the specific components of the CUL4A complex responsible for substrate recognition and recruitment, remain poorly characterized. Using biochemical and yeast two-hybrid approaches, Dr. Zhou's group identified several cellular proteins that specifically associate with CUL4A. One such interactor is the UV-damaged DNA binding proteins (DDB), a heterodimeric complex consisting of the 127 kD DDB1 and the 45 kD DDB2. DDBs are DNA damage sensors of the nucleotide excision repair pathway that is responsible for repairing helix-distorting DNA lesions induced by ultraviolet light (UV) irradiation or chemical carcinogens. Mutations in the *DDB2* gene  
*continued on page 9*

## Focus

by Daniel M. Knowles, MD

### The Department of Pathology and Laboratory Medicine Welcomes Dr. Attilio Orazi



Attilio Orazi, MD

The Department of Pathology and Laboratory Medicine welcomes Dr. Attilio Orazi, Professor of Pathology and Laboratory Medicine, who has joined us as Vice Chairman for Hematopathology and Director, Division of Hematopathology.

Dr. Attilio Orazi received his MD from the University of Milan, Italy in 1979. He pursued postgraduate training in General Medicine at Ballochmyle Hospital in Scotland, in Clinical and Laboratory Hematology at the Leicester Royal Infirmary in England and in Histopathology and Morbid Anatomy at the Northampton General Hospital in England. He completed his training at the Milan Tumor Institute under the direction of the renowned hematopathologist Professor Franco Rilke in 1985. He was certified by the American Board of Pathology in Anatomic Pathology in June, 1997 and in Hematology in August, 1998. He was appointed Assistant Attending Pathologist in the Division of Anatomic Pathology and Cytopathology at the National Cancer Institute in Milan, Italy and was promoted to a tenured staff position in 1990. He continued to serve at the Milan National Cancer Institute until 1992 when he was recruited to the Department of Pathology at the Indiana School of Medicine as Associate Professor of Pathology and Director of the Immunohistochemistry Laboratory within the Division of Hematopathology. He served in that capacity until 1998, at which time he was recruited as Director of the Division of Hematopathology and Professor of Pathology at the Columbia Presbyterian Medical Center. He remained in those roles until 2001 when he returned to Indiana University School of Medicine as Professor of Pathology with tenure and Director of the Division of Hematopathology. He remained there until I recruited him to the Weill Cornell Medical Center in July, 2008.

Dr. Attilio Orazi is an internationally renowned academic hematopathologist. His diagnostic expertise covers all areas of hematopathology, although he is particularly noted for his accomplishments as a bone marrow and spleen pathologist. Evidence in support of this is provided by requests for him to direct and/or participate in numerous post-graduate courses as well as to serve as the pathology consultant for major

clinical trials. He is a member of the Executive Committee of the Society for Hematopathology. He is also a member of the Scientific Committee of the European Bone Marrow Working Group, which is responsible for organizing the scientific agenda and selecting the expert panelists for their Annual Slide Workshops. This is the major international course focused on the teaching and education of bone marrow pathology to community and academic pathologists. Furthermore, he has directed courses concerning “Advances in Immunohistology in the Assessment of Bone Marrow Disorders” and “Neoplastic Disorders of the Spleen” for the United States and Canadian

Dr. Orazi also has a long track record of involvement in teaching medical students and in the education and training of pathology and hematology house staff. He actively participated in medical school teaching activities at the University of Indiana and at the Columbia University College of Physicians and Surgeons. In 2001 he organized and established the ACGME–approved Hematopathology Fellowship at the Columbia University College of Physicians and Surgeons and also served as Director of the Hematopathology Fellowship at Indiana University.

In addition to his clinical responsibilities, his academic and scholarly activities, and his involvement

**Dr. Attilio Orazi is an internationally renowned academic hematopathologist. His diagnostic expertise covers all areas of hematopathology, although he is particularly noted for his accomplishments as a bone marrow and spleen pathologist.**

Academy of Pathology. Dr. Orazi was also the Co-Organizer of the Workshop of the Society of Hematopathology in 2007. These activities have been supplemented by invitations to speak more than 70 times during the past few years at numerous universities and medical schools worldwide.

Dr. Orazi has published more than 130 peer reviewed papers in the medical and scientific literature. Most of these publications focus on clinical and diagnostic aspects of hematologic malignancy or represent collaborative efforts with basic scientists investigating the pathogenesis of hematologic neoplasia. Dr. Orazi is the senior author or a co-author of 12 chapters of the fourth edition of the *WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues*. These include all the chapters concerning myeloproliferative disorders. In addition, Dr. Orazi has authored numerous chapters in other textbooks and is co-author of the prominent textbooks *Disorders of the Spleen* and *Illustrated Pathology of the Bone Marrow*.

Dr. Orazi’s notable diagnostic expertise and wide ranging knowledge of hematologic malignancy has resulted in his invitation to participate in a number of NIH sponsored programs. He currently serves as the Pathology Chair for the clinical trial activities of the NIH-sponsored Myeloproliferative Disorders Research Consortium.

in teaching and education, Dr. Orazi has been also involved in a variety of administrative activities. He served on the Promotion and Tenure Committee, the Executive Committee, and on the Compensation Committee of the Department of Pathology at the University of Indiana School of Medicine. In 2007, he was named to the Board of Directors of the Indiana Pathology Institute.

In summary, Dr. Attilio Orazi is an internationally recognized hematopathologist who has maintained a very active academic profile worldwide, has directed a strong clinical research program for many years, has participated in a number of NIH-sponsored grants and clinical trials, and has participated actively in the administrative and teaching activities of the Departments in which he has been appointed. The Hematopathology Service at the Weill Cornell Medical Center is quite large, comprised of several faculty involved in clinical diagnostic activities, NIH-sponsored research programs and house staff education and training. I have formally organized this group into a Division of Hematopathology and recruited Dr. Attilio Orazi to serve as Director of that Division and also to assist me in directing the Department as a Vice Chair. I am certain he will contribute significantly to patient care, education and research at the Weill Cornell Medical Center. ■

## Keynotes

by *Domenick Falcone, PhD*

▶ During the last several months, **Dr. Yash Agrawal** has served on three of the College of American Pathologists (CAP) national resource committees. He is an active participant on the Toxicology Resource Committee which oversees the CAP's national proficiency testing program in toxicology and therapeutic drug monitoring, and the Pharmacogenetics working group which oversees nation wide proficiency testing in pharmacogenetics as related to personalized medicine. He also serves as a member of the Pharmacogenomics Committee which is tasked with developing a certificate course in the subject. Recently, he also has been invited to serve on the CLSI Subcommittee on Specimen Labels, which deals with technical and informatic considerations related to specimen labels.

▶ **Dr. Rebecca Baergen** traveled to Austria in September to teach a week long Advanced Course in Pediatric Pathology sponsored by the International Pediatric Pathology Association. She also taught a course in May in Salt Lake City, Utah on Perinatal Pathology sponsored by the Society for Pediatric Pathology. Dr. Baergen served on the Publications Committee for the Society for Pediatric Pathology at both the interim meeting and combined USCAP meeting. She also served on the Gynecologic Oncology Group pathology committee. Dr. Baergen presented a poster at the United States and Canadian Academy of Pathology meeting in Denver Colorado: Maternal Floor Infarction (MFI) and Biochemical Markers for Adverse Outcome (Loukeris K, Gelbar S, Chasen S, Baergen R).

▶ In October 2007, **Dr. Andrea Cerutti** gave a seminar on "Human B cells in health and disease" for our Pathology and Laboratory Medicine Grand Rounds. In November 2007, he traveled to Woods Hole to lecture on "The Regulation of IgA Class Switching by Epithelial Cells" at the New England Immunology Conference, where a student of his lab, Kang Chen, received the prestigious Charles A. Janeway Award. In the same month, Dr. Cerutti talked about "B cells at the Crossroad Between Innate and Adaptive Immune Responses" at the University of Minnesota. In December 2007, he was invited by Mount Sinai School of Medicine to give a lecture on "Innate Regulatory Networks in Mucosal IgA Class Switching." In January 2008, he lectured on IgA class switching at the Joint MIVAC International Conference in Gothenburg, Sweden, and at a NIAID Workshop on Immune Defense Mechanisms at the Mucosal Surface in Bethesda. In

March 2008, Dr. Cerutti gave a keynote lecture on mucosal IgA responses at the World Immune Regulation Meeting-II in Davos, Switzerland, and in the same month he lectured on "IgA Responses and HIV Infection" at the European Institute of Oncology in Milan, Italy. In April 2008, Dr. Cerutti was invited to talk at a major symposium of the 2008 American Association of Immunologists/Experimental Biology Meeting in San Diego on "BAFF and APRIL: Key Innate Regulators of Immunoglobulin Heavy Chain Class Switching." In May 2008, he lectured on "Mucosal, B Cell and Ig Switching Interactions in inflammation: How Bacteria Support Mucosal Immunity" at the Henry Kunkel Society Meeting held in Santa Margherita, Italy. In addition to lecturing, Dr. Cerutti served on various committees. In November 2007, he served as External Advisory Board Member to evaluate a SPORE grant application from MD Anderson Cancer Center. He served on three NIH-NIAID review committees for P01 and R01 applications. Furthermore, Dr. Cerutti served as lecturer in the Host Defenses Course for WMC medical students, both in New York and Qatar. He also continued to serve as chairperson of the Admission to Candidacy Exam Proposal Committee for the Immunology and Microbial Pathogenesis Program. Lastly, he was awarded a 5-year R01 grant (\$250,000/yr) by NIH-NIAID to study the role of the HIV protein Nef in antibody responses. He was also awarded a 5-year Irma T. Hirschl Career Scientist Award (\$35,000/yr) and a 1-year Cornell CLL Research Center Grant (\$50,000) to perform studies on antibody responses to bacterial polysaccharides and on CLL B cells, respectively.

▶ **Dr. Ethel Cesarman** is currently serving on the Committee of Review, the Cancer Center Internal Advisory Board and as the Pathology Representative and Secretary to the General Faculty Council. She is also the Director of the Immunology Program Training Grant. Dr. Cesarman was an invited speaker at the following institutions: Pathobiology Graduate Program, School of Public Health, University of Washington in Seattle (October 2007); Institute of Biomedicine/Biochemistry, Biomedicum Helsinki, Finland (Nov 2007); New York Pathology Society, New York (January 2008); and the Department of Microbiology, University of Virginia in Charlottesville (March 2008). She was an invited speaker for the Distinguished Lecture Seminar, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine (February 2008). Dr. Cesarman was a speaker at the Scientific Symposium of the National Meeting of the NIH-funded Centers for AIDS Research (CFARs) in San Diego, CA (November 2007) and the International Conference on Burkitt Lymphoma and Related Lymphoproliferative Disorders, Kampala, Uganda (February 2008). In these presentations, Dr. Cesarman spoke about her work on

the molecular mechanisms of lymphomagenesis caused by the Kaposi's sarcoma herpesvirus and Epstein-Barr virus, and the recent progress by her laboratory in this field. In November she served as an Opponent in the PhD thesis defense of Annika Jarviluoma in Helsinki, Finland. At Weill Cornell, she served in the ACE oral examination committee for Ying-Ju Hou.

Two abstracts from Dr. Cesarman's laboratory were presented orally at the 11th International Workshop on KSHV and Related Agents in Birmingham, UK (Jul 2008): **Gianna Ballon** gave a presentation entitled "Generation of vFLIP transgenic mice: a model to study KSHV-associated lymphomagenesis;" and Dr. Cesarman presented for **Daniel DiBartolo** an abstract entitled "Heightened Redox Status of Primary Effusion Lymphoma Cells can be Exploited Therapeutically by Decreasing Resistance to Oxidative Stress." Dr. DiBartolo presented two posters at the International Herpesvirus Workshop in Estoril, Portugal (July 2008). **Iliaria Guasparri** presented a poster entitled "Transcriptional Regulation of TRAF2 by Epstein Barr Virus Latent Membrane Protein 2A" at the International Conference on Burkitt Lymphoma and Related Lymphoproliferative Disorders in Kampala, Uganda (February 2008).

▶ **Dr. Selina Chen-Kiang** continues to serve on the Board of Scientific Counselors at the National Cancer Institute, the Medical and Scientific Committee and the Educational Sub-committee of the Leukemia and Lymphoma Society as well as the Board of Directors of the New York Chapter of the Society, among other advisory and review committees. These activities have kept her very busy in site visits, and grant and policy reviews.

In the past year, effort in the Chen-Kiang laboratory has led to the development of the first strategy to selectively target the cell cycle in cancer in combination therapy, which is now in a Phase I/II clinical trial in multiple myeloma in collaboration with colleagues at Weill Cornell and other institutions in the US. Dr. Chen-Kiang was invited to speak about "Emerging Novel Therapies to Control Cell Division in Cancer" at the Journey of Hope at the Leukemia and Lymphoma Society in October of 2007. She was an invited symposium speaker at the American Society of Clinical Oncology Annual Meeting in May of 2007, where she presented "Targeting Cdk4/6 in Combination Therapy: a New Class of Cancer Therapy." At the International Myeloma Workshop in Kos, Greece, in June of 2007, Dr. Chen-Kiang presented her work on Cell Cycle Control of plasma cell differentiation and myeloma pathogenesis. In the Lymphoma and Myeloma Conference in October of 2008, she gave two talks on "Cell Cycle Control of Myeloma: from bench to the bedside" and "Cell Cycle-

*continued on page 4*



## Keynotes

continued

Based Therapy in Myeloma and Lymphoma.” In the upcoming ASH meeting in 2008, Dr. Chen-Kiang is invited to speak in the Symposium dedicated to “Emerging Approaches to Apoptotic and Cell Cycle Control of Hematopoietic Malignancies” along with three eminent investigators Drs. Jerry Adams, Steven Fesik and John Reed. Apart from meeting presentations, Dr. Chen-Kiang has been invited to speak about targeting the cell cycle in hematopoietic malignancies at many academic institutions, including the University of Pittsburgh Medical School in January of 2009.

► **Dr. Domenick J. Falcone** has been named Vice-Chair of the Core of Basic Sciences Committee, which oversees the first and second year medical college curriculum. In February, Dr. Falcone was invited by the Department of Surgery to lecture on “Prostanoid Receptor EP4: the Nexus Between PGE2, MMPs and Inflammation.” Dr. K.M. Faisal Khan attended the annual meeting of the American Association of Experimental Pathology in San Diego, CA (April), and presented the poster “MMP-1 and MMP-3 Stimulate Macrophage MMP-9 Expression by Up-Regulating Components of the PGE2 Biosynthetic Pathway” (K.M.F. Khan, M. L. Steenport, B. Du and A.J. Dannenberg and D.J. Falcone). In May and September, Dr. Falcone served on Program Project Grant (P01) Review Committees for the NHLBI. In addition, he served on the abstract selection committee for the annual meeting of the American Heart Association, New Orleans, LA (November). During the convocation in June, Dr. Falcone was named to the Senior List by the Class of 2008 for excellence in teaching.

► **Dr. Syed Hoda** lectured on various breast pathology and surgical pathology-related topics in multiple national and international venues including the ASCP National Meeting in New Orleans, LA (October 2007); School of Breast Oncology in Atlanta, GA (November 2007); ASCP Weekend of Pathology in Las Vegas, NV (February 2008); Loma Linda University School of Medicine, Loma Linda, CA (February 2008); Mahidol University-Royal SriRaj Hospital in Bangkok, Thailand (March 2008); Ohio State Pathology Society in Columbus, OH (May 2008); and at University of Cairo Hospital in Egypt (June 2008). Together with Dr. Rosanny Espinal-Witter, Dr. Hoda presented a poster on Needle Core Biopsies of the Male Breast at the USCAP Annual Meeting in Denver, CO (March 2008). Earlier this year, Dr. Syed Hoda was appointed an Editor of *American Journal of Clinical Pathology*, the official

journal of the *American Society of Clinical Pathology*.

► **Dr. Xiangao Huang** (Instructor) and Dr. Eline Menu (postdoctoral fellow), two members of the Chen-Kiang lab, were proud recipients of travel fellowships to give oral presentations at the American Society of Hematology Annual Meeting in December 2007. Dr. Huang presented “Targeting CDK4/6 in Combination Therapy Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma,” and Dr. Eline Menu spoke about “Targeting CDK4/6 and the Cell Cycle in Combination with Bortezomib in the 5T33MM Myeloma Model.”

► In May 2008, **Dr. Joan G. Jones** chaired the President’s Symposium for the New York Pathological Society. This year, the theme was lung pathology and participants included Dr. William Travis, Dr. Sanja Dacic, Dr. Kevin Leslie, Dr. Eugene Mark, Dr. Kelly Butnor, Dr. Mary Beasley, and Dr. Tom Colby. The lectures were broad in their scope and very well received. Dr. Jones has been re-elected to serve another term as the Society’s President.

► **Dr. Daniel M. Knowles**, Chairman and Pathologist-in-Chief, continues to direct the Tutorial on Neoplastic Hematopathology. He has directed the Tutorial for the past 11 years. This is widely considered the premier postgraduate course in Hematopathology offered in the United States. This five-day course covers all aspects of malignant lymphoproliferative and myeloproliferative disease occurring in nodal, bone marrow and extranodal locations. The faculty includes a small roster of outstanding, internationally recognized expert hematopathologists. This year, the course was held in Boca Raton, Florida in January 2008. In addition to directing the Tutorial, Dr. Knowles lectured on “Pathology of Acquired Immunodeficiency Syndrome.” Dr. Knowles actively participated in the Annual Meeting of the United States and Canadian Academy of Pathology held in Denver, Colorado in March 2008. In addition to attending the annual meetings of the several editorial boards upon which he serves, Dr. Knowles co-authored four abstracts with other members of the Weill Cornell Hematopathology group and residents and fellows. In September 2008, Dr. Knowles attended the Annual Meeting of the Northeast Pathology Chairs in Bermuda. In addition to serving as Program Chairman for the meeting, Dr. Knowles led a spirited discussion concerning the economic opportunities and challenges facing academic pathology departments. In addition, Dr. Knowles continues in his role as Chief Medical Officer of the Weill Cornell Physician Organization. He also serves as Chair of the Strategic Plan III Clinical Implementation Committee. This committee is charged with coordinating all clinical programs and recruitments included in Strategic Plan III and in the planning

initiatives of the Physician Organization. The committee is responsible for developing recommendations to the Dean for sequencing priority funding and investments in people, space and programs. Dr. Knowles also co-chairs with Dr. Steve Corwin, Executive Vice President and Chief Operating Officer of NewYork-Presbyterian Hospital, the Board of Directors of Weill Cornell Imaging at NewYork-Presbyterian Hospital. Lastly, he serves as Chairman of the Internal Advisory Board charged with developing the administrative, clinical and scientific infrastructure necessary to eventually develop an NCI-designated Comprehensive Cancer Center at the Weill Cornell Medical Center.

► In 2008, **Dr. Debra G.B. Leonard** became a member of the newly formed Institute of Medicine’s Roundtable on Translating Genomics-Based Research for Health. As part of the Centers for Disease Control and Prevention’s project on Evaluation of Genomic Applications in Practice and Prevention (EGAPP), Dr. Leonard chairs the EGAPP Stakeholders Group, which focuses on the translation of EGAPP recommendations on the appropriate use of specific genomic tests into clinical practice. She continues to work as a member of the Association for Molecular Pathology’s Professional Relations Committee and the College of American Pathologists’ Council on Government and Professional Affairs and the Personalized Healthcare Committee. Within the department, she works with **Dr. Hanna Rennert**, Director, Molecular Pathology Laboratory, to facilitate the growth of molecular pathology testing and resident education.

► **Dr. Cynthia M. Magro** was an invited speaker at the annual Allergic and Atopic Dermatitis Conference held in New York City where she spoke on cutaneous immune reactions to infectious triggers, having published several papers in that particular area. In March, she was an invited speaker at the United States and Canadian Academy of Pathology where she spoke on angiocentric lesions of the head and neck. The talk was published in a review format in the new journal *Head and Neck Pathology*. In May, Dr. Magro was the invited speaker along with Drs. Stanley Robboy and Neil Crowson at the Illinois Society of Pathologists. She gave a talk on the combined WHO/EORTC classification of cutaneous lymphoma. In June, Drs. Magro, Crowson and Mihm gave their annual comprehensive dermatopathology course in Austin, Texas. This is a four-day course wherein she and her colleagues provide a comprehensive review of non-neoplastic and neoplastic dermatopathology directed at the dermatology, dermatopathology and general pathology audience. In September, Dr. Magro was an invited speaker at the Harvard Dermatopathology update course talking

## Keynotes

*continued*

about cutaneous lymphoma and its mimics, blistering disease and the application of immunofluorescence in diagnosing inflammatory skin disease. In October, Dr. Magro was invited to lecture on the Pathology of Cutaneous Lymphoma at the annual Lymphoma and Myeloma Conference held in New York City.

► **Dr. Edyta Pirog** presented two abstracts at the 97th Annual Meeting of the United States and Canadian Academy of Pathology, Denver, CO, 2008: “Immunoprofile of Mucinous and Microglandular Adenocarcinomas of the Endometrium” (MA Chekmareva, L Ellenson, EC Pirog) and “Prevalence of Mucosal and Cutaneous Human Papillomaviruses in Different Histologic Subtypes of Vulvar Carcinoma and Correlation with p16 Overexpression” (EC Pirog, M De Koning, W Quint).

► **Dr. Hanna Rennert** presented a poster entitled “Development of a Comprehensive and Efficient Molecular Diagnostic Assay for the Autosomal Dominant Polycystic Kidney Disease (ADPKD) genes, *PKD1* and *PKD2*” at the American Society of Human Genetics meeting (October 2007). This work described the development of a novel and comprehensive method for the identification of sequence variations in ADPKD genes, using a mismatch-specific DNA endonuclease and DHPLC. The work also described the development of an *in-silico* algorithm for evaluating the pathogenic potential of gene variations of unknown significance. She also presented this work in the Department of Pathology Grand Rounds (December 2007). With coauthors Drs. Rebbeck and Zeigler-Johnson of the University of Pennsylvania, Dr. Hanna Rennert wrote a review entitled “Prostate Cancer in Men of African Descent: Implications for Global Disparities in Incidence and Outcomes” published in *Can J Urology* in February, 2008 as a part of the African Organization for Research and Training in Cancer (AORTIC) meeting that took place in Cape Town in October, 2007. As a part of a Multi-Institute Collaboration group focused on studying Genetic Risks for Metastatic and Recurrent Prostate Cancer, she now continues working on further characterization of the role of high-risk gene polymorphisms recently identified by The Cancer Genetic Markers of Susceptibility (CGEMS) group for this disease in the Asian Indian sample. Dr. Rennert was selected Chair Elect and Chair of the Genetic Subdivision of the Association of Molecular Pathology (AMP) and is a member of the AMP Meeting Program Committee in 2008-09.

► **Dr. Paul Peter Rosen** is the recipient of the 2008 Fred Waldorf Stewart Award, bestowed annually by the Department of Pathology at Memorial Sloan-Kettering Cancer Center (MSKCC) on an individual who has contributed in extraordinary fashion to our understanding of human neoplastic disease. Congratulations on this outstanding recognition!

► **Dr. Surya V. Seshan** was an invited speaker in the Postgraduate Course on renal pathology on “Renal Lesions in SLE” at American Society of Nephrology (November 1-4, 2007). She was invited to speak at the annual session of the Indian Society of Nephrology, New Delhi, India on “Glomerular Diseases with Organized Deposits: The Role of Immunofluorescence and Electron Microscopy” (December 12-16, 2007). She served as a Visiting Professor in the Department of Pathology and Nephrology, and spoke on “Renal Manifestations of Dysproteinemias” and conducted a Transplant Pathology case review session at the Sri Ramachandra Medical College and Research Institute, Chennai, India (January 22, 2008). She was an invited lecturer at the IX International CME in Surgical Pathology and Cytopathology at NIMHANS, Bangalore, India (January 26-28, 2008) on “Organized Glomerular Deposits” and “Transplant Pathology Slide Seminar” and spoke on “Thrombotic Microangiopathy – an Update” at the Apollo Hospital, Hyderabad, India (January 31, 2008). Dr. Seshan is currently Vice President of the Renal Pathology Society as well as the chairperson of its International Committee. Dr. Seshan served as an abstract reviewer for “Renal Pathology: Clinical/ Diagnostic renal pathology and laboratory medicine,” American Society of Nephrology (ASN) annual meeting, in Philadelphia (November 5-9, 2008).

► **Dr. Wayne Tam** was an invited speaker at the 7th International Symposium on Hodgkin Lymphoma in November, 2007 in Cologne, Germany. He gave a presentation on “The Role of MicroRNA in Regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg Cells.” He was also invited to give a lecture on “PRDM1 and Lymphomagenesis” at the 12th World Congress on Advances in Oncology in October, 2007 in Crete, Greece. In January, he was elected to the Editorial Board of the journal *Molecular Medicine Reports*. He recently received the World Scientist Forum International Award and has been named “Eminent Scientist of the Year 2008” in the field of cancer research and gene biology in the United States, from the International Research Promotion Council (IRPC). The award was made in the field of “Cancer Research and Gene Biology,” based on his work on microRNAs and tumor suppressor genes in the pathogenesis of lymphomas and leukemias. In addition, he was the

recipient of a pilot award grant from the Weill Cornell Clinical and Translational Center (CTSC) for his research proposal in follicular lymphomas and microRNA.

► **Dr. Rita K. Upmacis** was the recipient of the Alice Bohmfalk Charitable Trust medical research grant for her studies that have focused on understanding the implications of interactions between nitric oxide and the enzyme cyclooxygenase (COX) during atherosclerosis. In April, Dr. Upmacis participated in the 235th American Chemical Society (ACS) National Meeting in New Orleans and presented a talk entitled “Inducible Nitric Oxide Synthase Contributes to Biopterin Oxidation and Protein Tyrosine Nitration During Atherogenesis.” Her presentation was one of eleven chosen for a press conference that was broadcasted live on the web. A press release entitled “Atherosclerosis Damage” accompanied this broadcast. During the past year, Dr. Upmacis was invited to review grants for the Asthma and Allergic Diseases Cooperative Research Centers (U19) study section in Gaithersburg, Maryland, and for the Academy of Sciences for the Developing World. She served a second term on an America Cancer Society Award selection committee and was also invited to serve on a thesis defense committee in the Department of Chemistry, Columbia University. Dr. Upmacis also became an Editor of *Lipid Insights*, a peer-reviewed open-access online journal that covers all aspects of lipids.

► **Dr. Y. Lynn Wang** became board-certified in Molecular Genetic Pathology in September 2007 and a Fellow of College of American Pathologists in November. The Molecular Hematopathology Laboratory that she directs passed the CAP inspection in October 2007 with no deficiencies. She was invited as a consultant to the Center for Disease Control and Prevention’s Get-RM (Genetic Testing Reference Materials) program meeting in November. The program focuses on standardization of reference materials in genetic testing. In December, Dr. Wang was invited again to the BCR-ABL International Standardization Meeting held in Atlanta. A new publication from this group can now be found in *Blood* (Branford et al, e-pub 8/6/08). Dr. Wang’s group also published two papers regarding the frequencies of JAK2 mutations in lympho- and myelo-proliferative disorders. She has traveled to several venues to present work from her group. In November 2007, she presented a poster entitled “Expression of Error-Prone DNA Polymerases in B Cell Lymphomas” at the Association for Molecular Pathology’s Annual Meeting in Los Angeles. In January 2008, Dr. Wang was invited to visit the Mayo Clinic Jacksonville and the University of Florida at Gainesville and to present a seminar on “Detection of JAK2 Mutations in the Chronic

*continued on page 6*

## Keynotes

continued

Myeloproliferative Disorders.” In July 2008, she was invited to give a talk on “Chronic Myeloproliferative Neoplasms: Molecular Diagnosis and Monitoring” at the Chinese Academy of Medical Sciences in Beijing. She is quoted and pictured in the September 2008 issue of CAP Today in the article “Class Action for Myeloproliferative Disorders.”

Dr. Wang's laboratory has been focusing on signal transduction in B cell lymphomas. They have published an article entitled “Tyrosine Kinase Inhibition In Diffuse Large B-Cell Lymphoma: Molecular Basis For Anti-Tumor Activity And Drug Resistance of Dasatinib” *Leukemia* (Yang et al, *Leukemia*, 22, 1755-66). Dr. Wang was awarded a travel grant to present the poster on this work at the meeting of the American Society for Clinical Investigation in Chicago. To complete the translation from bench to bedside, Dr. Wang has teamed up with some of her clinical colleagues to develop a phase II clinical trial of dasatinib in large cell lymphoma. She was invited to talk about “Targeting Early Events of B-Cell Receptor Signaling In Non-Hodgkin Lymphomas: Molecular Basis For Anti-Tumor Activity And Drug Resistance of Dasatinib” at the Hospital of University of Pennsylvania in Sept 2008. The lab continues to use various signal transducer inhibitors to probe the pathogenesis of various non-Hodgkin lymphomas and leukemias. Regarding her work on PPARγ, Dr. Wang presented a poster, “PPARγ Promotes Lymphocyte Survival via A Mitochondrial Pathway Mediated by GSK-3β,” at the 49th American Society of Hematology annual meeting held in Atlanta. She also wrote a review article “To Live or To Die: Prosurvival Activity of PPARγ In Cancers” that has been published in a special Issue of *PPAR Research*. She continues to serve as a reviewer including for *Journal of Molecular Diagnostics*, *Diagnostic Molecular Pathology*, *Leukemia*, *PPAR Research*, and *Leukemia and Lymphoma*. For updated information, please visit Dr. Wang's website at <http://www.med.cornell.edu/research/lynnwang>.

► **Dr. Rhonda K. Yantiss** was invited to lecture on serrated colorectal polyps at the 2007 national meeting of the Collaborative Group of the Americas on Inherited Colorectal Cancer in San Diego California. She was also asked to speak in honor of Dr. Donald Antonioli during the Rodger C. Haggitt Gastrointestinal Pathology Society companion meeting at the 2008 United States and Canadian Academy of Pathology National Meeting in Denver Colorado. Dr. Yantiss coauthored six abstracts at that meeting: she delivered a platform

presentation and was the senior author on four abstracts presented by our gastrointestinal pathology fellow, Dr. Gustavo Alvarez, and three residents, Dr. Raanan Sela, Dr. Jeannelyn Estrella, and Dr. Gloria Young, the latter of which was also selected as a platform presentation. Dr. Yantiss was selected to serve on the education committee of the Gastrointestinal Pathology Society, as well as on the abstract review committee of the gastrointestinal pathology section of the United States and Canadian Academy of Pathology. She serves as an ad hoc reviewer for eleven journals and was recently appointed as a section editor of the *Archives of Pathology and Laboratory Medicine*. This year, Dr. Yantiss wrote a chapter in a premier text of gastrointestinal pathology edited by Dr. Robert D. Odze, co-authored eleven peer-reviewed articles, and published two review articles related to inflammatory bowel disease and serrated colorectal neoplasia. Her collaborative efforts with Dr. Andrew Dannenberg resulted in a research award from the New York Crohn's foundation. Dr. Yantiss has also been active in the Weill Cornell Medical College: she serves on the Continuing Medical Education committee and co-directs the gastrointestinal pathophysiology section of the second year medical student course.

► **Dr. Pengbo Zhou** received the Irma T. Hirsch Career Scientist Award for his efforts to engineer hematopoietic stem cells for expansion and allogeneic transplantation (2007-12; \$175,000). He received a grant from the New York State Stem Cell Science ESSC Board to study the derivation of lympho-hematopoietic stem cells from human embryonic stem cell lines (2008; \$50,000). In addition, Drs. Malcolm Moore and Zhou were awarded a grant from the Tri-Institutional Stem Cell Initiative to study the derivation of lympho-hematopoietic stem cells from human embryonic stem cell lines (2008-09; \$100,000). Finally, Dr. Zhou received the extraordinarily important and prestigious award from the Starr Cancer Consortium to study small molecule inhibitors of the ubiquitin pathway in antagonizing skin carcinogenesis (2008-10; \$1,000,000). Dr. Zhou presented the laboratories latest findings on ubiquitin-proteolytic control of DNA repair and skin carcinogenesis at several institutions including: Duke University (Jan 2007), CUNY/Hunter College (April 2007), University of Massachusetts Medical School in Worcester (April 2008) and Boston University School of Medicine (May 2008). In June, he spoke at the NYC Bio Meet-Up at the NYU School of Medicine (June 2008) on the development of skin cancer therapeutics. ■

## Newly Awarded Grants in Pathology

### **Starr Cancer Consortium Research Grant Award**

Title: Small Molecule Inhibitors of the Ubiquitin Pathway in Antagonizing Skin Carcinogenesis  
Principal Investigator: Pengbo Zhou, PhD  
Period of Support: 09/01/07-08/31/08  
Total Direct Costs: \$250,000

### **Starr Cancer Consortium Research Grant Award**

Title: Determining Germline Risk Factors for Lethal Prostate Cancer: The Role of Copy Number Variations in Prostate Cancer Progression  
Principal Investigator: Mark A. Rubin, MD  
Period of Support: 07/15/08-07/14/09  
Total Direct Costs: \$400,000

### **Leukemia and Lymphoma Society Translational Research Grant**

Title: Cell Cycle Control of Multiple Myeloma  
Principal Investigator: Selina Chen-Kiang, PhD  
Period of Support: 10/01/08-09/30/10  
Total Direct Costs: \$360,036

### **Irma T. Hirsch/Monique Weill-Caulier Trust Career Scientist Award**

Title: Regulation of Antibody Responses to Bacterial Polysaccharides  
Principal Investigator: Andrea Cerutti, MD  
Period of Support: 01/01/08-12/31/12  
Total Direct Costs: \$175,000

### **Multiple Myeloma Research Foundation Fellows Award**

Title: Novel Cdk 4/6 Inhibitor Combination Therapy  
Principal Investigator: Xiangao Huang, PhD  
(Dr. Selina Chen-Kiang's Lab)  
Period of Support: 02/01/08-01/31/09  
Total Direct Costs: \$68,182

### **Clinical and Translational Science Center Pilot Award**

Title: Towards the Identification of Germline Risk Factors for Lethal Prostate Cancer  
Principal Investigator: Francesca Demichelis, PhD  
Period of Support: 06/01/08-05/31/09  
Total Direct Costs: \$50,000

### **Clinical and Translational Science Center Pilot Award**

Title: MicroRNA Profiling and Functional Oncogenomics in Follicular Lymphoma  
Principal Investigator: Wayne Tam, MD PhD  
Period of Support: 01/01/08-05/31/08  
Total Direct Costs: \$50,000



## Faculty Publications in 2008

**Baergen RN:** The placenta as witness. *Clinics Perinatol* 34:393-407, 2007.

**Baergen RN:** Cord abnormalities, structural lesions and cord accidents. *Sem Diag Pathol* 24:23-32, 2007.

Poppas DP, Hochshtein AA, **Baergen RN**, Loyd E, Chen J, Felsen D: Nerve sparing ventral clitoroplasty preserves dorsal nerves in congenital adrenal hyperplasia. *J Urol* 178:1802-1806, 2007.

Hui P, Wang HL, Chu P, Yang B, Huang J, **Baergen RN**, Sklar J, Yang XJ, Soslow RA: Absence of Y chromosome in human placental site trophoblastic tumor. *Mod Pathol* 20: 1055-1060, 2007.

Polyorides AD, Kalish RB, Witkin SS, **Baergen RN:** Fetal Polymorphisms in anti-inflammatory cytokine and beta-adrenergic receptor genes associated with placental pathological lesions. *Int J Gynecol Pathol* 27: 79-85, 2008.

**Cerutti A:** The regulation of IgA class switching. *Nat Rev Immunol* 8:421-434, 2008.

**Cerutti A**, Rescigno M: The biology of intestinal IgA responses. *Immunity* 28:740-750, 2008.

**Cerutti A:** Location, location, location – B cell differentiation in the gut lamina propria. *Mucosal Immunol* 1:8-10, 2008.

Xu W, Santini PA, Matthews AJ, **Chiu A**, Plebani A, He B, Chen K, **Cerutti A:** Viral double-stranded RNA triggers Ig class switching by activating upper respiratory mucosa B cells through an innate TLR3 pathway involving BAFF. *J Immunol* 181:276-287, 2008.

Brinker BT, Krown SE, Lee JY, **Cesarman E**, Chadburn A, Kaplan LD, Henry DH, Von Roenn JH: Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. *Cancer* 112:1083-8, 2008.

**Guasparri I**, **Bubman D**, **Cesarman E:** EBV LMP2A mediates LMP1 signaling and survival of lymphoma cells through TRAF2 regulation. *Blood* 111:3813-3820, 2008.

**Di Bartolo D**, Cannon M, **Liu YF**, Renne R, Chadburn A, Boshoff C, **Cesarman E:** Kaposi's sarcoma herpesvirus LANA inhibits TGF-2 signaling through epigenetic silencing of the TGF-2 type II receptor. *Blood* 111:4731-4740, 2008.

**Nie K**, **Gomez M**, Tan L, Landgraf P, **Liu Y**, Garcia JF, Fan S, Wright K, Chadburn A, Tuschl T, **Knowles DM**, **Tam W:** MicroRNA-mediated translational repression of *PRDM1* in Hodgkin/Reed-Sternberg cells – a potential pathogenetic lesion in Hodgkin lymphoma. *Am J Pathol* 173:242-52, 2008.

**Wang YL**, **Lee JW**, **Kui JS**, Chadburn A, Cross NCP, **Knowles DM**, Coleman M: Evaluation of JAK2<sup>V617F</sup> in B- and T-cell neoplasms: Identification of JAK2<sup>V617F</sup> mutation of undetermined significance (JMUS) in the bone marrow of three individuals. *Acta Haematol* 118: 209-14, 2007.

**Yang C**, **Lu P**, Lee FY, Chadburn A, Barrientos JC, Leonard JP, Ye F, Zhang D, **Knowles DM**, **Wang YL:** Tyrosine kinase inhibition in diffuse large B-cell lymphoma: Molecular basis for anti-tumor activity and drug resistance of dasatinib. *Leukemia Prepub* 7/3/08.

Menu E, Garcia J, Huang X, **Di Liberto M**, Toogood P, Chen I, Vanderkerken K, **Chen-Kiang S:** A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. *Cancer Research* 68: 5519-5523, 2008.

Niesvizky R, Naib T, Christos PJ, Jayabalan DS, Furst JR, Jalbrzikowski J, Zafar F, Mark T, **Lent R**, Pearse RN, **Ely S**, Leonard JP, Mazumdar M, **Chen-Kiang S**, Coleman S: (2007) Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment naïve patients undergoing front-line lenalidomide and dexamethasone therapy. *Br J Haematol* 138: 640-3, 2007.

Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, Jalbrzikowski J, Pearse RN, Zafar F, Pekle K, Larow A, **Lent R**, Mark T, Cho HJ, Shore T, Tepler J, Harpel J, Schuster M, **Mathew S**, Leonard JP, Mazumdar M, **Chen-Kiang S**, Coleman S: BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete and overall response rates in treatment-naïve symptomatic multiple myeloma. *Blood* 111: 1101-9, 2007.

Martin P, Chadburn A, Christos P, Furman R, Ruan J, Joyce MA, Fusco E, Glynn P, Elstrom R, Niesvizky R, Feldman EJ, Shore TB, Schuster MW, **Ely S**, **Knowles DM**, **Chen-Kiang S**, Coleman M, Leonard P: Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. *Ann Oncol* 7: 1327-30, 2008.

Chung SM, Kao J, Hyjek E, **Chen YT:** p53 in esophageal adenocarcinoma: A critical reassessment of mutation frequency and identification of 72Arg as the dominant allele. *Int J Oncol* 31:1351-1355, 2007.

Seil I, Frei C, Sultmann H, Knauer SK, Engels K, Jäger E, Zatloukal K, Pfreundschuh M, Knuth A, **Chen YT**, Jungbluth AA, Stauber RH, Jäger D: The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer. *Int J Cancer* 120:2635-2642, 2007.

Silva Jr WA, Gnjatich S, Ritter E, Chua R, Cohen T, Hsu M, Jungbluth AA, Altorki NK, **Chen YT**, Old LJ, Simpson AJ, Caballero OL: PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses. *Cancer Immunol* 7:18, 2007.

Chung SM, **Chen YT**, Panczykowski A, Schamberg N, Klimstra SS, **Yantiss RK:** Serrated polyps with “intermediate features” of sessile serrated polyp and microvesicular hyperplastic polyp: A practical approach to the classification of non-dysplastic serrated polyps. *Am J Surg Pathol* 32:407-412, 2008.

Chen YB, Tu JJ, Kao J, Zhou XK, **Chen YT:** Survivin as a useful adjunct marker for the grading of papillary urothelial carcinoma. *Arch Pathol Lab Med* 132:224-231, 2008.

Theurillat JP, Zurrer-Hardi U, Varga Z, Barghorn A, Saller E, Frei C, Storz M, Behnke S, Seifert B, Fehr M, Fink D, Rageth C, Linsenmeier C, Pestalozzi B, **Chen YT**, Knuth A, Jager D, Moch H: Distinct expression patterns of the immunogenic differentiation antigen NY-BR-1 in normal breast, testis and their malignant counterparts. *Int J Cancer* 122:1585-1591, 2008.

John T, Caballero OL, Svobodova SJ, Kong A, Chua R, Browning J, Fortunato S, Deb S, Hsu M, Gedye CA, Davis ID, Altorki N, Simpson AJ, **Chen YT**, Monk M, Cebon J: ECSA/DPPA2 is an embryo-cancer antigen that is co-expressed with cancer-testis antigens in non-small-cell lung cancer. *Clin Cancer Res* 14:3291-3298, 2008.

Webber BA, **Cushing MM**, Li S: Prognostic significance of flow cytometric immunophenotyping in acute myeloid leukemia. *Int J Clin Exp Pathol* 1:124-133, 2008.

Ness PM, **Cushing MM:** Oxygen therapeutics: pursuit of an alternative to the donor red blood cell. *Arch Pathol Lab Med* 131:734-741, 2007.

**Upmacis RK**, Crabtree MJ, **Deeb RS**, Shen H, Lane PB, Benguigui LE, Maeda N, **Hajjar DP**, Gross SS: Profound bipterin oxidation and protein tyrosine nitration in tissues of ApoE-null mice on an atherogenic diet: contribution of inducible nitric oxide synthase. *Am J Physiol Heart Circ Physiol* H2878-87, 2007.

**Deeb RS**, **Upmacis RK**, **Lamon B**, Gross SS, **Hajjar DP:** Maintaining equilibrium by selective targeting of cyclooxygenase pathways: promising offensives against vascular injury. *Hypertension* 51:1-7, 2008.

**Brandt SM**, **Young GQ**, **Hoda S:** “The Rosen Triad”: tubular carcinoma, lobular carcinoma in situ and columnar cell lesions. *Adv Anat Pathol* 15:140-146, 2008.

Arora N, **Hoda S**, Osborne MP, Swistel AJ, Tousimis E, Pressman PI, Simmons RM: Sentinel node positivity rates with and without frozen section for breast cancer. *Ann Surg Oncol* 15:256-261, 2008.

**Robinson BD**, **Amin BD**, **Hoda S:** Alternaria simulating metastatic carcinoma in cytokeratin-stained axillary sentinel lymph node sections. *Breast J* 14:120-121, 2008.

Cellini C, **Hoda S**, Spigland N: Lupus-associated vasculitis manifesting as acute appendicitis in a 16-year-old girl. *Pediatr Rheumatol* J 27:10-11, 2008.

## Faculty Publications in 2008 *continued*

**Hoda S, Robinson BD:** Crib death: sudden unexplained death of infants. *JAMA* 299:1073-1074, 2008.

**Hoda S, Hoda R:** Histology for pathologists. *Adv Anat Pathol* 15:124, 2008.

**Hoda SA, Hoda RS:** Clinicopathologic foundations of medicine. A Review. *JAMA* 298:2073-2074, 2007.

Gildea J, **Lefkowitz JB:** Acquired platelet disorders, transfusion medicine. *Checksample*. ASCP Press 51:29-41, 2008.

Walczak S, Brimhall BB, **Lefkowitz J:** Diagnostic Cost Reduction Using Artificial Neural Networks: The Case of Pulmonary Embolism. In: *Healthcare Information Systems and Informatics: Research and Practices*, edited by J Tan, Medical Information Science Reference. Hershey, PA, 2008.

Yanaba K, Bouaziz JD, Matsushita T, **Magro CM**, St Clair EW, Tedder TF: B-lymphocyte contributions to human autoimmune disease. *Immunol Rev* 223:284-99, 2008.

Westall GP, Snell GI, McLean C, Kotsimbos T, Williams T, **Magro C:** C3d and C4d deposition early after lung transplantation. *J Heart Lung Transpl* 27:722-8, 2008.

**Dyrsen ME**, Iwenofu OH, Nuovo G, **Magro CM:** Parvovirus B19-associated catastrophic endothelialitis with a Degos-like presentation. *J Cutan Pathol* Jun 4 [Epub ahead of print], 2008.

Awad H, Suntres Z, Heijmans J, Smeak D, Bergdall-Costell V, Christofi FL, **Magro C**, Oglesbee M: Intracellular and extracellular expression of the major inducible 70kDa heat shock protein in experimental ischemia-reperfusion injury of the spinal cord. *Exp Neurol* Apr 6 [Epub ahead of print], 2008.

Minard-Colin V, Xiu Y, Poe JC, Horikawa M, **Magro CM**, Hamaguchi Y, Haas KM, Tedder TF: Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fc $\gamma$ RI, Fc $\gamma$ RIII, and Fc $\gamma$ RIV. *Blood* May 21 [Epub ahead of print], 2008.

Siscovick JR, Zapolski T, **Magro C**, Carrington K, Prograis S, Nussbaum M, Gonzalez S, Ding W, Granstein RD: Polypodium leucotomos inhibits ultraviolet B radiation-induced immunosuppression. *Photodermatol Photoimmunol Photomed* 24:134-41, 2008.

Crowson AN, **Magro CM**, Mihm MC Jr: Interface dermatitis. *Arch Pathol Lab Med* 132:652-66, 2008.

**Magro CM, Schaefer JT:** T- and B-cell clonally restricted pseudolymphoma in the setting of phytoestrogen therapy. *J Eur Acad Dermatol Venereol* May 22:642-3. Epub, 2008.

Stewart S, Fishbein MC, Snell GI, Berry GJ, Boehler A, Burke MM, Glanville A, Gould FK, **Magro C**, Marboe CC, McNeil KD, Reed EF, Reinsmoen NL, Scott JP, Studer SM, Tazelaar HD, Wallwork JL, Westall G, Zamora MR, Zeevi A, Yousem SA: Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. *J Heart Lung Transplant* 26:1229-42, 2007.

**Magro CM, Schaefer JT**, Waldman J, Knight D, Seilstad K, Hearne D: Terbinafine-induced dermatomyositis: a case report and literature review of drug-induced dermatomyositis. *J Cutan Pathol* 35:74-81, 2008.

**Magro CM, Dyrsen M**, Kerns MJ: Cutaneous lesions of dermatomyositis with supervening fibrosis. *J Cutan Pathol* 35:31-9, 2008.

Crowson AN, **Magro C**, Miller A, Mihm MC Jr: The molecular basis of melanomagenesis and the metastatic phenotype. *Semin Oncol* 34:476-90, 2007.

**Magro CM**, Weirnerman DJ, Porcu PL, Morrison CD: Post-transplant EBV-negative anaplastic large cell lymphoma with dual rearrangement: a propos of two cases and review of the literature. *J Cutan Pathol* 1:1-8, 2007.

Agnese DM, Maupin R, Tillman B, Pozderac RD, **Magro C**, Walker MJ: Head and neck melanoma in the sentinel lymph node era. *Arch Otolaryngol Head Neck Surg* 133:1121-4, 2007.

Hamadani M, **Magro CM**, Porcu P: CD4+ CD56+ haematodermic tumour (plasmacytoid dendritic cell neoplasm). *Br J Haematol* 140:122, 2008.

Plaza JA, Morrison C, **Magro CM:** Assessment of TCR-beta clonality in a diverse group of cutaneous T-Cell infiltrates. *J Cutan Pathol* 35:358-65, 2008.

**Magro CM**, Crowson AN: So called 'de novo intra-epidermal epithelioid melanocytic dysplasia' is melanoma in situ. *J Cutan Pathol* 34:812, 2007.


Barocas DA, **Mathew S**, DelPizzo JJ, Vaughan ED Jr, Sosa RE, Fine RG, **Akhtar M**, Scherr DS: Renal cell carcinoma sub-typing by histopathology and fluorescence in situ hybridization on a needle-biopsy specimen. *BJU Intl* 99:90-95, 2007.

Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, Girtman K, **Mathew S**, Ma J, Pounds SB, Su X, Pui CH, Relling MV, Evans WE, Shurtleff SA, Downing JR: Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. *Nature* 446:758-64, 2007.

Blinder VS, Chadburn A, **Mathew S**, Leonard JP: Improving outcomes for patients with Burkitt lymphoma and HIV. *AIDS Patient Care and STDs*. 22:175-187, 2008.

de Koning MN, Quint WG, **Pirog EC:** Prevalence of mucosal and cutaneous human papillomaviruses in

## Recent Faculty Textbook



Paul Peter Rosen, MD

different histologic subtypes of vulvar carcinoma. *Mod Pathol* 21:334-44, 2008.

**Rosen PP:** "Rosen's Breast Pathology, Third Edition" Lippincott, Williams and Wilkins, 2009. 1116 pages.

Jaggi JS, Carrasquillo JA, **Seshan SV**, Zanzonico P, Henke E, Nagel A, Schwartz J, Beattie B, Kappel BJ, Chattopadhyay D, Xiao J, Sgouros G, Larson SM, Scheinberg DA: Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor. *J Clin Invest* 117:2422-2430, 2007.

**Seshan SV:** Lupus vasculopathy and vasculitis: What is the difference and when do they occur? *Pathology Case Reviews* 214-221, 2007.

Hersh A, **Seshan SV**, Oleske J: An adolescent with history of chronic sinusitis and asthma. *J Resp Dis* 341-343, 2007.

Janakiraman H, Abraham G, Matthew M, Kuruvilla S, Panikar V, Solomon S, Kumaraswamy S, **Seshan SV**, Lesley N: Correlation of CD4 counts with renal disease in HIV positive patients. *Saudi J Kidney Dis Transpl* 19:603-607, 2008.

**Tam W, Gomez M, Kui N:** Significance of PRDM1b expression as a prognostic marker in diffuse large B-cell lymphomas. *Blood* 111:2488-2489, 2008.

**Wagner PL, Tam W**, Lau PY, Port JL, Paul S, Altorki NK, Lee PC: Primary esophageal large T Cell lymphoma mimicking esophageal carcinoma: A case report and literature review. *J Thorac Cardiovasc Surg* 135:957-958, 2008.

Zhang T, Kui N, **Tam W:** BIC/microRNA-155 is processed efficiently in Burkitt lymphomas. *Leukemia* 22:1795-1797, 2008.

**Yantiss RK**, Panczykowski A, Misdrayi J, Odze RD, **Rennert H, Chen YT:** Comprehensive study of non-dysplastic and dysplastic serrated polyps of the



## Faculty Publications in 2008 *continued*

vermiform appendix. *Am J Surg Path* 31: 1742-1753, 2007.

Zeigler-Johnson CM, **Rennert H**, Mittal RD, Jalloh M, Sachdeva R, Malkowicz SB, Mandhani A, Mittal B, Gueye SM, Rebbeck TR: Evaluation of prostate cancer characteristics in four populations worldwide. *Can J Urol* 15: 4056-64, 2008.

**Rennert H**, Zeigler-Johnson CM, Tan YC, Mittal RD, Sadowl CM, Finely MJ, Edwards J, Mandhani A, Mital B, Rebbeck TR: Analysis of the RNASEL/HPC1 and Macrophage Scavenger Receptor 1 in Asian-Indian advanced prostate cancer. *Urol Apr* 23 [Epub ahead of print], 2008.

Rebbeck RT, **Rennert H**, Walker AH, Spangler E, Panossian S, Walker K, Tran T, Patacsil-Coomes M, Wein AJ, Bruce Malkowicz S, Zeigler-Johnson C: Joint effects of inflammation and androgen metabolism on prostate cancer severity. *Int J Can June* 19 [Epub ahead of print], 2008.

Zeigler-Johnson CM, Spangler E, Jalloh M, Gueye SM, **Rennert H**, Rebbeck TR: Genetic susceptibility to prostate cancer in men of African descent: implications for global disparities in incidence and outcomes. *Can J Urol* 15:3872-82, 2008.

Jones RG, Bui T, White C, Madesh M, Krawczyk CM, Lindsten T, Hawkins BJ, Kubek S, Frauwrith KA, **Wang YL**, Conway SJ, Roderick HL, Bootman MD, Shen H, Foskett JK, Thompson CB: The proapoptotic factors Bax and Bak regulate T Cell proliferation through control of endoplasmic reticulum Ca(2+) homeostasis. *Immunity* 27:268-80, 2007.

**Wang YL**, Vandris K, Jones AV, Cross NCP, Christos P, Adriano F, Silver RT: JAK2 mutations are present in all cases of polycythemia vera. *Leukemia* 22:1289, 2008.

**Wang YL**, Miao Q: To live or to die: Pro-survival activity of PPAR $\gamma$  in cancers. *PPAR Research, Special Issue on PPARs: A Double-Edged Sword in Cancer Therapy* vol 2008, 1-13, 2008.

**Yang GCH**: Fine needle aspiraton biopsy. Chapter 8 In: *Salivary Gland Disorders*. (Ed: Meyers EN, Ferris RL). Springer-Verlag, Berlin Heidelberg 2007.

Alasio TM, Sun W, **Yang GCH**: Giant cell carcinoma of the lung. Impact of diagnosis and review of cytologic features. *Diagn Cytopathol* 35:555-9, 2007.

**Yang GCH**: On-site assessment of 6,797 ultrasound-guided thyroid fine-needle aspirates. *Am Soc Cytopathol Bulletin XLV* 51-58, 2008. ■

## Research Highlights

*continued*

were originally identified in patients suffering from the autosomal recessive disease xeroderma pigmentosum (complementation group E), which is characterized by sun sensitivity and predisposition to early onset of skin cancer. Dr. Zhou's laboratory has demonstrated that high levels of CUL4A, as seen in cancer patients, stimulate ubiquitination and degradation of DDB2, resulting in an overall decrease of UV-DDB activity for recognizing DNA photolesions. Using a combination of biochemical, cellular and genetic approaches, work in Dr. Zhou's laboratory uncovered a fundamental role of CUL4A in establishing the threshold of nucleotide excision repair capacities, underscoring the benefit of pharmacological attenuation of CUL4A ubiquitin ligase activity in conferring increased protection against carcinogenesis induced by environmental culprits, such as UV irradiation. A major focus of Dr. Zhou's research, namely, to translate these basic research findings into cancer prevention and novel anticancer therapeutic strategies was recently funded by the STARR Cancer Consortium.

### (2) CUL4A in Normal and Malignant Hematopoiesis

Another family of CUL4A targets Dr. Zhou's group identified using yeast two-hybrid screens is the HOX homeodomain proteins, which play critical roles in normal as well as malignant hematopoiesis. HOX genes are expressed in hematopoietic stem and progenitor cells and are downregulated during terminal differentiation. Uncontrolled HOX expression has been shown to promote leukemic transformation. Dr. Zhou demonstrated that CUL4A targets HOXA9 for ubiquitin-dependent proteolysis. The degradation signal (degron) is located within the homeodomain of HOXA9 and is conserved among all 39 HOX family members. CUL4A-mediated HOXA9 degradation is required for proper differentiation and maturation of myeloid progenitor cells. Dr. Zhou's studies revealed the critical role CUL4A plays in the self-renewal, expansion and differentiation of primary hematopoietic stem cells.

Several HOX genes (HOXA9, A10, A11, A13) are involved in chromosomal translocations with the nucleoporin NUP98 in acute myeloid leukemia (AML) patients. The resulting NUP98-HOX fusions display strong transcriptional activity and leukemogenic potential, but the mechanisms underlying the enhanced transforming activity of NUP98-HOX fusions remain largely elusive. Dr. Zhou's laboratory demonstrated that fusion with NUP98 rendered HOXA9 resistant to degradation by CUL4A, suggesting a new mechanism to prolong the action of the oncogenic NUP98-HOXA9 fusion. Microarray analysis detected elevated expres-

sion of many HOX and HOX co-factor genes in human umbilical cord blood CD34+ cells expressing NUP98-HOXA9. Current studies in Dr. Zhou's laboratory involves establishing mouse models defective for CUL4A-mediated HOXA9 degradation to evaluate this novel proteolytic control mechanism in leukemic transformation. Another emphasis of the hematopoietic project is to exploit what was learned to facilitate the *ex vivo* expansion of human hematopoietic stem and progenitor cells.

### (3) Protein Knockout Technology

The substrate specificity of a cellular ubiquitination pathway is conferred exclusively by the ubiquitin ligases. Dr. Zhou previously demonstrated the feasibility of harnessing the specificity of the SCF (Skp1, Cullin-1 and F-box-containing substrate receptor) ubiquitin ligase to target degradation of cellular proteins that are otherwise stable. Dr. Zhou's group has recently optimized the degradation vectors and achieved selective elimination of several key cellular proteins involved in cell growth control and tumorigenesis. The protein knockout system operates at the posttranslational level, and thus possesses unique and versatile properties in exploring the complexity of protein functions that are unattainable by RNAi, gene targeting, and antisense technologies. Using this system, Dr. Zhou's laboratory has demonstrated that (1) protein knockout can be exploited to delineate detailed protein functions dictated by subcellular distribution or posttranslational modification; (2) SCF can be engineered to target degradation of either a single protein or an entire family of proteins, and thereby probe functional redundancy in somatic cells; (3) protein knockout can be easily tuned to determine the magnitude of knockdown through controlled proteolysis; and (4) protein knockout operates across different eukaryotic species. In contrast, technologies that operate on the RNA level, such as RNAi, are strictly species-specific.

Dr. Zhou's current studies are aimed at developing the protein knockout system as a simple and efficient tool to generate loss of function mutations of specific gene products for functional analysis in mammals, and to evaluate whether specific cellular proteins are valid targets for therapeutic intervention. The long-term goals are (1) to apply the protein knockout technology in the functional genomic studies for assigning gene functions, and (2) to employ the protein knockout technology for establishment of novel assay systems for drug screening and target validation.

In summary, ubiquitin-dependent proteolysis is a fundamental regulatory pathway that governs a wide range of cellular processes. Understanding its mechanisms of action and targets it ubiquitinates under normal and pathological conditions will shed light on designing novel and target-oriented strategies for human disease intervention. ■

## Resident's Corner

by Debra G.B. Leonard, MD, PhD

### Welcome to Our New PGY-1 Residents

We are very pleased to welcome our four new first year residents who joined the Pathology Residency Training Program in July 2008.



Timothy D'Alfonso, MD



Kunal Karia, MD



Jiong Yan, MD, PhD



Amy Yang, MD

■ **Dr. Timothy D'Alfonso** is from North Kingstown, Rhode Island. He attended Villanova University for his undergraduate degree and received his MD from the Chicago Medical School, where he was a member of Alpha Omega Alpha. In his spare time, he enjoys running and biking in the city.

■ **Dr. Kunal Karia** is from Louisville, KY, and is thus an avid Louisville sports fan. Kunal received his BS from Virginia Commonwealth University and MD from the Medical College of Virginia.

■ **Dr. Jiong Yan** received her MD in 1998 from the Peking Union Medical College and her PhD in 2004 from the Baylor College of Medicine. Previously, she has been a Postdoctoral Associate at Baylor, where she has conducted research in molecular and human genetics.

■ **Dr. Amy Yang** received her MD in 2007 from the University of Texas Southwestern Medical School at Dallas. She completed a PGY-1 in Internal Medicine at Yale-New Haven Hospital, and has joined us to continue her residency training in Pathology.

### Highlight on Our Graduating Residents

Three of our residents completed Anatomic and Clinical Pathology training in July 2008, and have entered fellowship training programs. **Dr. Bijal Amin**, who was our Chief Resident in 2007-2008 and received the Distinguished House Staff Award in 2008, remains here in the joint Memorial Sloan-Kettering Cancer Center–NewYork-Presbyterian Hospital Dermatopathology Fellowship. **Dr. Emily Loyd**, who wants to focus her career in Gastrointestinal Pathology, is completing a GI Fellowship in the joint Memorial Sloan Kettering Cancer Center–NewYork-Presbyterian Hospital Gastrointestinal Pathology Fellowship. **Dr. Garron Solomon** is headed for a career in Dermatopathology and is currently completing a Dermatopathology fellowship at the Ackerman Academy of Dermatopathology in New York City. **Dr. Patrick Wagner** rejoined pathology for two years to complete his Anatomic Pathology training, in the midst of his Surgery training. He has returned to his surgery residency also at NYPH. We wish Bijal, Emily, Garron and Patrick all the best!

### Information about Our Current Residents

■ **Dr. Suzanne Brandt** received her MD from Georgetown University and is completing her fourth year of residency. She will begin her cytopathology fellowship at Memorial Sloan-Kettering Cancer Center in July 2009.

■ **Dr. Yingbei Chen** is currently serving as the Chief Resident in her fourth year of AP/CP training. She received her MD from Peking Union Medical College in 1998 and PhD from Johns Hopkins University in 2004. With an interest in genitourinary pathology, she is taking extended time for research in the genomics of prostate cancer with Dr. Mark Rubin, and will begin a GU fellowship at Johns Hopkins University Hospital in July 2009.

■ **Dr. Claudia Cohn** received her BS from George Washington University and her PhD from Johns Hopkins University. She received her MD in 2004 from Louisiana State University Medical School and following graduation, began pathology residency training at Louisiana State University Medical Center. She recently received a grant from the American Society of Hematology to work on viral transmission in hematopoietic stem cell transplants. She is completing her

AP/CP training this year and will be beginning her fellowship in Transfusion Medicine at the University of California San Francisco in July 2009. She enjoys backpacking, cooking and playing with her 4 year old daughter.

■ **Dr. Kristina Loukeris** is a fourth year AP/CP resident. She received her BA from Columbia University and her MD from Chicago Medical School, where she was a member of the Pathology Honor Society. She will remain at NewYork-Presbyterian Hospital for a Cytology Fellowship in 2009.

■ **Dr. Raanan Sela** earned his BS in Psychology from the University of Florida and his MD from the University of Miami. He is completing his fourth year of AP/CP training this year and will commence a one-year Gastrointestinal and Liver Pathology Fellowship at Columbia University Medical Center in July 2009. In his time away from pathology, Raanan enjoys cinema, bike riding, and producing videos.

■ **Dr. Gloria Young** is a fourth year resident who earned her undergraduate degree from Wellesley and her MD from Boston University. Gloria will begin her surgical pathology fellowship at Memorial Sloan-Kettering Cancer Center in 2009 followed by a combined Memorial Sloan-Kettering Cancer Center – NewYork-Presbyterian Hospital gastrointestinal pathology fellowship in 2010.

■ **Dr. Suzanne Arinsburg** is a third year clinical pathology resident. She is looking forward to starting her combined Transfusion Medicine fellowship at the New York Blood Center and Columbia University Medical Center next year.

■ **Dr. Molly Dyrsen** is currently serving as the Assistant Chief Resident in her third year of AP/CP training. She received her BS from the University of Alabama and her MD from the University of Louisville, where she was Alpha Omega Alpha. She has worked closely with Dr. Cynthia Magro on several projects in Dermatopathology.

■ **Dr. Rosanny Espinal-Witter** is currently in her third year of AP/CP training. She received her BS from Mercy College and her MD from the Albert Einstein College of Medicine. She is interested in every aspect of Hematology and will be applying for a Hematopathology Fellowship for the year of 2010-2011. Dr. Espinal-Witter was born in the Dominican Republic and she just welcomed a new member, Rojric, to her now family of four.



## Resident's Corner

*continued*

■ **Dr. Jeannelyn Estrella** received her BS and MD degrees from the University of California San Diego. She will complete her AP training this year and begin a fellowship in surgical pathology in July 2009 followed by a fellowship in gastrointestinal pathology in 2010, both at the MD Anderson Cancer Center.

■ **Dr. Brian Robison** is currently a third year resident in Anatomic Pathology. He attended Washington University in St. Louis for his undergraduate degree, where he majored in Biology and Spanish, and then entered Weill Cornell Medical College for medical school. He will begin a fellowship in genitourinary pathology at Johns Hopkins University Hospital in July 2009.

■ **Dr. Joanna Chan** is a second year AP/CP resident who received her BA and MS from Johns Hopkins University. She received her MD from Pennsylvania State University School of Medicine.

■ **Dr. Adam Gersten** is a second year AP/CP resident who received his BA from Cornell University in Ithaca and his MD from the Albert Einstein College of Medicine in New York.

■ **Dr. Kate Maloney** is a second year AP/CP resident who graduated from the University of Massachusetts Medical School in Worcester, MA.

■ **Dr. Nicole Panerelli** is a second year AP resident who is a native New Yorker. She received her BA in government and political philosophy from Georgetown University and her MD from New York Medical College. Nicole hopes to pursue a career in gastrointestinal pathology. She maintains an interest in political science and current events.


■ **Dr. Dara Rosenman** is a second year AP/CP resident who grew up in Plainview, New York. She received her BA and MD degrees from Boston University. Dara was married this fall in Manhattan.

■ **Dr. Steve Salvatore** is a second year AP/CP resident. He received his undergraduate degree from Wake Forest and his MD from St. Louis University.


■ **Dr. Jeremy Segal** received his BA from Dartmouth College and his PhD from Rockefeller University and his MD from Weill Cornell Medical College, as part of the Tri-Institutional MD/PhD program. ■



*(left to right) Drs. Estrella, Dyrsen, Loukeris, Segal.*



*(left to right) Drs. Yao-Tseng Chen and Yingbei Chen.*



*(left to right) Drs. Raanan Sela and Rhonda Yantiss.*



## New Post-Graduate Courses

### ► 2009 Update in Dermatopathology February 12, 2009

Metropolitan Club, New York City  
Course Director: **Cynthia M. Magro, MD**

#### Target Audience

Dermatologists, plastic and general surgeons and dermatopathologists.

#### Course Goals and Objectives

The participants of this course will develop an understanding of the cutaneous T & B cell lymphomas, including subtyping, prognosis and treatment. There will be an extensive overview of subtypes of Melanoma with histology parameters to prognosticate Malignant Melanoma. The attendees will gain further insight in the value of Immunofluorescence as a diagnostic adjunct in CVD. They will also have an understanding of how the skin is a potential venue in which to study peripheral neuropathy syndromes.

### ► The Tutorial on Pathology of the GI Tract, Pancreas and Liver November 9-13, 2009

Boca Raton Marriott, Boca Raton, Florida  
Course Director: **Rhonda K. Yantiss, MD**

#### Target Audience

General surgical pathologists and pathologists-in-training.

#### Course Goals and Objectives

This course is designed to update physicians on advances in our understanding of gastrointestinal diseases, address problems faced during the pathologic evaluation of tissue samples, and provide pathologists with a framework for interpretation of both histologic patterns of disease and results of molecular analyses.

#### Accreditation

34.0 AMA PRA Category 1 Credit(s)<sup>™</sup>

For more information  
or to register for all courses,  
please contact:  
**Ms. Jessica Pfeifer**  
(212) 746-6464

jep2018@med.cornell.edu  
<http://www.cornellpathology.org>

## Upcoming Post-Graduate Course

### ► Tutorial on Neoplastic Hematopathology January 26-30, 2009

Marco Island Marriott Resort, Golf Club and Spa  
Marco Island, Florida

#### Target Audience

Pathologists, pathologists-in-training and medical oncologists/hematologists.

#### Accreditation

35.25 AMA PRA Category 1 Credit(s)<sup>™</sup>

### Conference Agenda

SUNDAY JANUARY 25		6:00-8:00 pm ..... Registration		
Day 1 MONDAY JANUARY 26	7:00 am .....	Registration	12:15-12:30 pm ..... Questions	
	7:45-8:00 am .....	Introductory Remarks Daniel M. Knowles, MD	12:30-2:00 pm ..... Lunch	
	Morning Session Chairperson: Daniel M. Knowles, MD		Afternoon Session Chairperson: Elaine S. Jaffe, MD	
	8:00-9:00 am .....	Normal Lymphoid Tissue Structure and Function NancyLee Harris, MD	2:00-3:00 pm .....	Flow Cytometry in the Diagnosis and Classification of Hematologic Neoplasia Steven H. Kieff, MD
	9:00-9:15 am .....	Questions	3:00-3:15 pm .....	Questions
	9:15-10:45 am .....	Reactive Lymphadenopathies Lawrence M. Weiss, MD	3:15-3:30 pm .....	Break
10:45-11:00 am .....	Questions	3:30-4:45 pm .....	Molecular Analysis in the Diagnosis and Classification of Lymphoproliferative Disorders Adam Bagg, MD	
11:00-11:15 am .....	Break	4:45-5:00 pm .....	Questions	
11:15-12:15 pm .....	Immunophenotypic Analysis in the Diagnosis and Classification of Lymphoproliferative Disorders Elaine S. Jaffe, MD	5:30-7:00 pm .....	Reception	
Day 2 TUESDAY JANUARY 27	Morning Session Chairperson: Adam Bagg, MD		Afternoon Session Chairperson: NancyLee Harris, MD	
	8:00-9:00 am .....	Classification of Lymphoid Neoplasms NancyLee Harris, MD	1:30-2:30 pm .....	Nodal and Extranodal Marginal Zone Lymphomas Steven H. Swerdlow, MD
	9:00-9:15 am .....	Questions	2:30-2:45 pm .....	Questions
	9:15-10:15 am .....	Diffuse Aggressive B-cell Lymphomas Jonathan Said, MD	2:45-4:15 pm .....	Incidence of Peripheral T-cell Lymphoma Subtype Elaine S. Jaffe, MD
	10:15-10:30 am .....	Questions	4:15-4:30 pm .....	Questions
	10:30-10:45 am .....	Break	4:30-4:45 pm .....	Break
10:45-11:45 am .....	Small B-cell Neoplasms NancyLee Harris, MD	4:45-5:45 pm .....	Cutaneous Lymphomas Steven H. Swerdlow, MD	
11:45-12:00 pm .....	Questions	5:45-6:00 pm .....	Questions	
12:00-1:30 pm .....	Lunch			
Day 3 WEDNESDAY JANUARY 28	Morning Session Chairperson: Lawrence M. Weiss, MD		Afternoon Session Chairperson: Jerome E.S. Burke, MD	
	8:00-9:30 am .....	Hodgkin Lymphoma Jerome E.S. Burke, MD	12:15-1:45 pm .....	Lunch
	9:30-9:45 am .....	Questions	1:45-2:15 pm .....	Natural Killer (NK) Cells & NK-cell Leukemias and Lymphomas William G. Morice, MD, PhD
	9:45-10:30 am .....	Immunodeficiency-associated Lymphoproliferative Disorders (IPLD) Daniel M. Knowles, MD	2:15-2:30 pm .....	Questions
	10:30-10:45 am .....	Questions	2:30-3:30 pm .....	Histiocytic and Dendritic Proliferations Lawrence M. Weiss, MD
	10:45-11:00 am .....	Break	3:30-3:45 pm .....	Questions
11:00-12:00 pm .....	Acquired Immunodeficiency Syndrome (AIDS) Daniel M. Knowles, MD	3:45-4:00 pm .....	Break	
12:00-12:15 pm .....	Questions	4:00-5:00 pm .....	Spleen Jerome E.S. Burke, MD	
		5:00-5:15 pm .....	Questions	
Day 4 THURSDAY JANUARY 29	Morning Session Chairperson: Attilio Crati, MD		Afternoon Session Chairperson: John Anastasi, MD	
	8:00-9:15 am .....	B-and T-cell Chronic Lymphoproliferative Disorders Kathy Foucar, MD	12:15-1:45 pm .....	Lunch
	9:15-9:30 am .....	Questions	1:45-3:00 pm .....	Precursor Lymphoid Neoplasms Robert W. McKenna, MD
	9:30-10:30 am .....	Plasmablast Dyscrasias Robert W. McKenna, MD	3:00-3:15 pm .....	Questions
	10:30-10:45 am .....	Questions	3:15-3:30 pm .....	Break
	10:45-11:00 am .....	Break	3:30-4:45 pm .....	Acute Myeloid Leukemia Kathy Foucar, MD
11:00-12:00 pm .....	Evaluation of Bone Marrow Biopsies for Lymphoma LoAnn Peterson, MD	4:45-5:00 pm .....	Questions	
12:00-12:15 pm .....	Questions	5:00-6:00 pm .....	Myelodysplastic Syndromes Attilio Crati, MD	
		6:00-6:15 pm .....	Questions	
Day 5 FRIDAY JANUARY 30	Morning Session Chairperson: LoAnn Peterson, MD		Afternoon Session Chairperson: LoAnn Peterson, MD	
	8:00-9:00 am .....	Chronic Myelogenous Leukemia John Anastasi, MD	10:45-11:30 am .....	Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) Attilio Crati, MD
	9:00-9:15 am .....	Questions	11:30-11:45 am .....	Questions
	9:15-10:15 am .....	The BCRABL-negative Myeloproliferative Neoplasms John Anastasi, MD	11:45-12:30 pm .....	Systemic Mastocytosis LoAnn Peterson, MD
	10:15-10:30 am .....	Questions	12:30-12:45 pm .....	Questions
	10:30-10:45 am .....	Break	12:45 pm .....	Concluding Remarks Daniel M. Knowles, MD



Volume 15 • Fall 2008

Editor Daniel M. Knowles, MD  
Co-Editor Carl F. W. Wolf, MD  
Managing Editor Gina L. Imperato, MPA  
Design JBRH Advertising & Design, Inc.

The Pathologist is a bi-annual publication of the  
Department of Pathology and Laboratory Medicine

at NewYork-Presbyterian Hospital/Weill Cornell  
Medical Center. If you have any comments or  
questions, please contact: Managing Editor,  
Gina L. Imperato • tel: (212) 746-6464  
e-mail: [glimpera@med.cornell.edu](mailto:glimpera@med.cornell.edu)  
[www.cornellpathology.org](http://www.cornellpathology.org)